{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:06:07Z","timestamp":1790337967480,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1373,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1582-4934.2011.01296.x","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T23:54:42Z","timestamp":1299023682000},"page":"2735-2744","source":"Crossref","is-referenced-by-count":69,"title":["Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic"],"prefix":"10.1111","volume":"15","author":[{"given":"Jacob E.","family":"Shabason","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Tofilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Camphausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,28]]},"reference":[{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB1|cit1","unstructured":"Central Brain Tumor Registry of the United States 2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006 http:\/\/www.cbtrus.org\/2010-NPCR-SEER\/CBTRUS-WEBREPORT-Final-3-2-10.pdf"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1215\/S1152851703000620","article-title":"Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis","volume":"6","author":"Lamborn","year":"2004","journal-title":"Neuro-oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/jnci\/djj411","article-title":"New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"98","author":"Neglia","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM198810203191601","article-title":"Tumors of the brain and nervous system after radiotherapy in childhood","volume":"319","author":"Ron","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB5|cit5","first-page":"88","volume-title":"Diagnostic pathology of nervous system tumours","author":"Ironside","year":"2002"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB6|cit6","unstructured":"The Cancer Genome Atlas http:\/\/cancergenome.nih.gov"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB7|cit7","doi-asserted-by":"crossref","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","author":"McLendon","year":"2008","journal-title":"Nature"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1517\/14728220902942348","article-title":"Glioblastoma multiforme: a review of therapeutic targets","volume":"13","author":"Kanu","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1227\/00006123-198803000-00003","article-title":"Survival after stereotactic biopsy of malignant gliomas","volume":"22","author":"Coffey","year":"1988","journal-title":"Neurosurgery"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide\u2002versus\u2002radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB16|cit16","unstructured":"US Food and Drug Administration http:\/\/www.fda.gov"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"87s","DOI":"10.1200\/jco.2009.27.15_suppl.2000","article-title":"Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme (abstract)","volume":"27","author":"Lai","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB19|cit19","unstructured":"Clinicaltrials.gov http:\/\/www.clinicaltrials.gov"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archneurol.2010.5","article-title":"Recent advances in therapy for glioblastoma","volume":"67","author":"Clarke","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.2003.tb05964.x","article-title":"Histone deacetylases: unique players in shaping the epigenetic histone code","volume":"983","author":"Thiagalingam","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J Cell Biochem"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1038\/onc.2009.117","article-title":"HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer","volume":"28","author":"L\u00f3pez-Soto","year":"2009","journal-title":"Oncogene"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2007.11.6202","article-title":"Inhibition of histone deacetylation: a strategy for tumor radiosensitization","volume":"25","author":"Camphausen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.20774","article-title":"Enhancement of\u2002in vitro\u2002and\u2002in vivo\u2002tumor cell radiosensitivity by valproic acid","volume":"114","author":"Camphausen","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/0008-5472.CAN-03-2630","article-title":"Enhanced radiation-induced cell killing and prolongation of gamma H2AX foci expression by the histone deacetylase inhibitor MS-275","volume":"64","author":"Camphausen","year":"2004","journal-title":"Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ijrobp.2004.03.001","article-title":"Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor","volume":"59","author":"Kim","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1667\/RR3192","article-title":"Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors","volume":"1","author":"Zhang","year":"2004","journal-title":"Radiat Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1158\/0008-5472.CAN-06-0049","article-title":"Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer","volume":"66","author":"Geng","year":"2006","journal-title":"Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ijrobp.2009.01.068","article-title":"Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo\u2002effects and relevance of histone acetylation status","volume":"74","author":"Folkvord","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cbr.2009.0629","article-title":"HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells","volume":"24","author":"Chen","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-04-0537","article-title":"Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation","volume":"10","author":"Camphausen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-09-0038","article-title":"Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown\u2002in vitro\u2002and as intracranial xenografts","volume":"8","author":"Baschnagel","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1535-7163.MCT-06-0022","article-title":"Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci","volume":"5","author":"Munshi","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ijc.20117","article-title":"Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl) amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells","volume":"110","author":"Zhang","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","article-title":"Enhancement of radiation response in osteosarcoma and rhabomyosarcoma cell lines by histone deacetylase Inhibition","volume":"78","author":"Blattmann","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1083\/jcb.200209065","article-title":"Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response","volume":"160","author":"Kao","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1158\/0008-5472.CAN-09-3848","article-title":"Three-dimensional cell growth confers radioresistance by chromatin density modification","volume":"70","author":"Storch","year":"2010","journal-title":"Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0070-2153(05)73006-4","article-title":"Histone deacetylation as a target for radiosensitization","volume":"73","author":"Cerna","year":"2006","journal-title":"Curr Top Dev Biol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB46|cit46","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"Kim","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/carcin\/bgp079","article-title":"Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis","volume":"30","author":"Chung","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1080\/09553000050176243","article-title":"Inhibition of repair of X-ray-induced DNA double-strand breaks in human lymphocytes exposed to sodium butyrate","volume":"76","author":"Stoilov","year":"2000","journal-title":"Int J Radiat Biol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB49|cit49","first-page":"263","article-title":"HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity","volume":"23","author":"Purrucker","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.317.3.3","article-title":"Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy","volume":"3","author":"Chung","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"Suppl","key":"10.1111\/j.1582-4934.2011.01296.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/j.ijrobp.2008.06.1542","article-title":"Acute toxicity in a phase II clinical trial of valproic acid in combination with temodar and radiation therapy in patients with glioblastoma multiforme (abstract 2094)","volume":"72","author":"Kamrava","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB52|cit52","first-page":"2437","article-title":"Influence of valproic acid on outcome of high-grade gliomas in children","volume":"28","author":"Masoudi","year":"2008","journal-title":"Anticancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(10)70058-9","article-title":"Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study","volume":"11","author":"Ree","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccr.2008.12.001","article-title":"Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis","volume":"15","author":"Fotheringham","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1073\/pnas.0913912107","article-title":"HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy","volume":"107","author":"Khan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737140.8.3.413","article-title":"Histone deacetylase inhibitors in lymphoma and solid malignancies","volume":"8","author":"Rasheed","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","article-title":"Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer","volume":"26","author":"Blumenschein","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/JTO.0b013e3181952478","article-title":"Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study","volume":"4","author":"Traynor","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1111\/j.1582-4934.2011.01296.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nurt.2006.11.007","article-title":"Valproic acid: second generation","volume":"4","author":"Bialer","year":"2007","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Cellular and Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1582-4934.2011.01296.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1582-4934.2011.01296.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T12:53:25Z","timestamp":1685969605000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1582-4934.2011.01296.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,28]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01296.x","relation":{},"ISSN":["1582-1838"],"issn-type":[{"value":"1582-1838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,28]]}}}